Northland lowered the firm’s price target on MiMedx (MDXG) to $10 from $12 and keeps an Outperform rating on the shares as the firm further adjusts FY26 and FY27 estimates to reflect near-term uncertainty arising from CMS’s flat-rate reimbursement for skin substitutes. Despite this near-term reset, longer term, the firm expects MiMedx to gain market share in the wound care segment while sustaining double-digit growth in its surgical recovery business, the analyst tells investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG:
- MiMedx price target lowered to $10 from $12 at Lake Street
- MiMedx Group Updates Strategy in Wound Care Markets
- MiMedx enters agreement with Regen Lab to distribute RegenKit-WoundGel in U.S.
- MiMedx announces publication in Journal of Inflammation on effects of Purion
- MiMedx price target lowered to $10 from $12 at Mizuho